Guide

What to consider when building a channel strategy for a rare disease product

A checklist for biopharma companies

Evaluating channel strategy options for a rare disease product is an essential element of commercialization. Biopharma companies should ask themselves these five questions to ensure their novel therapy reaches the right patients at the right time.

Enter your information below to download the checklist. 

Pardot Form

Related resources

Article

From AI to regulatory layering and convergence: Key takeaways from RAPS Euro Convergence 2026

Article

How U.S. pricing reform is reshaping global market dynamics

Guide

Cell and gene therapy playbook for payer engagement: Translating payer expectations into actionable market access strategies